PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Largest T cell clinical trial in solid tumors heralds new era in precision immunotherapy

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed

2024-11-11
(Press-News.org) The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, multisite trial recruited 330 advanced nasopharyngeal (NPC) cancer patients in 23 sites across Singapore, Malaysia, Thailand, Taiwan and the United States. The trial did not show an overall survival benefit for the entire patient cohort but a subset analysis combining outcomes of US, Singapore and Taiwanese sites, showed better progression free survival and overall survival. Results suggest that T cell therapy success would be enhanced by identifying the biomarkers in patients and within the cell therapy, to guide precision delivery.

Singapore, 11 November 2024 – The largest ever clinical trial of T cell therapy for solid tumours has ended, heralding a new era for precision T cell therapy. Led by a Singapore clinician-scientist, the multinational, phase III VANCE trial demonstrates that Singapore has the expertise and capabilities to run a large-scale global cell therapy trial. Results were published in the high impact factor journal, Annals on Oncology (JIF: 56.7), in October 2024.

“The planning, establishment and execution of the VANCE trial - including the large-scale manufacturing, storage, shipment, and delivery of high-quality T cells as treatments to patients’ bedsides across the world - is a monumental task and achievement. This is testament to the expertise across disciplines and institutions involved, showcasing Singapore’s ability to accomplish very complex cell therapy at the highest level,” said VANCE trial lead and study first author, Professor Toh Han Chong, Senior Consultant, Division of Medical Oncology and Deputy Chief Executive Officer (Strategic Partnerships), National Cancer Centre Singapore (NCCS).

“This international T cell therapy trial driven by Singapore's biotech and the National Cancer Centre Singapore represents a significant milestone. The delivery of high-quality T cells at large scale has been a major barrier for extending the applications of these therapies. To have achieved this goal when T cell therapy was in its infancy makes this Singapore-led achievement even more commendable,” said Professor Cliona Rooney, Baylor College of Medicine, Houston, Texas and one of the pioneers of T cell therapy.

What is T cell therapy?

T cell therapy is a type of immunotherapy that harnesses the body’s immune cells to fight cancer. It is developed by extracting cancer-recognising T cells from a person’s own blood or from another person, growing or genetically modifying them in the laboratory, then reintroducing them into the body to fight cancer cells. The most well-known type of T cell therapy is CAR-T cell therapy, which has been approved for use by the US FDA since 2017 to treat blood cancers such as acute leukaemia, lymphoma and multiple myeloma.

Laying the foundation of the VANCE trial

Prof Toh and his team at the Laboratory of Cell Therapy and Cancer Vaccine at NCCS have been driving research to develop novel ways to treat Asian-endemic cancers for over 20 years. Nasopharyngeal carcinoma (NPC) is a common cancer in males in Singapore and Southern China with an incidence of 8.9 per 100,000 males and 25 per 100,000 males, respectively. Current mainstay treatment of early and locally advanced NPC is radiotherapy and chemoradiotherapy but once NPC spreads beyond the originating site, treatment is largely not curative with median survival currently at 21 to 29 months.

There have been efforts to find more effective treatments for advanced NPC. NPC is closely associated with the Epstein-Barr virus (EBV), making NPC a good candidate to treat with immunotherapy targeting EBV. Small studies have shown that EBV-specific cytotoxic T cell (EBV-CTL) therapy, a type of T cell therapy, produces clinical responses and clinical benefit in NPC patients.  

Between 2008 to 2011, Prof Toh’s team conceptualised and led a Phase II single arm clinical trial in patients with recurrent or metastatic NPC at NCCS with 35 patients with advanced stage 4 NPC. They were given 6 cycles of EBV-CTL therapy after platinum-based combination chemotherapy treatment and results showed that adding the T cell therapy after first line chemotherapy generated promising clinical benefits compared to historical trials with subjects who only received chemotherapy. In this study, the median survival was 29.9 months, compared to median survival then which was generally 11 to 12 months. One patient who achieved complete clearance of NPC disease survived for nearly 10 years.

Executing the VANCE trial

Following the promising NCCS Phase II trial of EBV-CTL therapy for NPC, the VANCE trial, a global, multi-centre, randomised, open-label Phase III clinical trial of T cell therapy was launched, with Prof Toh as the overall coordinating principal investigator. Collaborators were from international medical institutions such as Tan Tock Seng Hospital (TTSH), Universiti Malaya Medical Centre, King Chulalongkorn Memorial Hospital, National Taiwan University Hospital, Stanford School of Medicine, UCSF School of Medicine, Massachusetts General Hospital and Baylor College of Medicine.

A total of 330 patients were enrolled between July 2014 and January 2020 at 23 trial sites in Singapore, Malaysia, Thailand, Taiwan and the United States. Participants were randomly divided into two groups – one that received chemotherapy followed by EBV-CTL therapy, and one that received chemotherapy alone. Treatment for this group consisted of two stages: 4 cycles of chemotherapy (gemcitabine and carboplatin) and 6 cycles of EBV-CTL therapy (totalling over 1 billion precision targeting T cells for each patient) starting 2 to 4 weeks after the completion of chemotherapy treatment. The group receiving chemotherapy, alone, underwent 6 cycles of chemotherapy.

Trial outcomes uncover ways to refine T cell therapy

Of the 330 patients on the VANCE trial, 154 patients completed the study. Median overall survival for participants on the trial was 25 months for the chemotherapy and EBV-CTL therapy group and 24.9 months in the chemotherapy only group. Results demonstrated that chemotherapy and EBV-CTL therapy was safe to use but that there was no overall survival improvement for the entire cohort of patients. Notably, in a subset analysis of patients enrolled in the combined US, Singapore and Taiwan sites, patients in the chemotherapy and EBV-CTL therapy group had better progression free survival and overall survival compared to the chemotherapy only arm.

This points to the opportunity to refine the approach to generate positive outcomes. The next steps for the team will be to identify biomarkers in the patient characteristics including their own immune system and biomarkers in the EBV CTL therapy product to improve outcomes through improvement in cell therapy design.

“T cell therapies are not standardised but personalised and called a ‘living therapy’ as they comprise the body’s T cells that are alive, which grow and expand in the body to kill cancer, sometimes for many years. Our trial results indicate that more efforts are needed to improve how T cell therapies are developed and administered to optimise treatment outcomes for patients, and we have now started on these studies,” said Prof Toh.

A new era in precision T cell therapy

“Adapted cell therapy by re-educating T cells against viral surface proteins is an effective and safe treatment. To our knowledge, the VANCE trial is the largest completed T cell therapy trial in solid cancers and is a significant contribution to the field. The benefit to patients in an exploratory subgroup within the VANCE trial warrants further investigation and a comprehensive analysis of the Phase II EBV CTL trial may identify biomarkers to help this quest,” said Principal Investigator for the VANCE trial at TTSH and study senior author, Assistant Professor Jens Samol, Senior Consultant, Medical Oncology, TTSH.

Efforts are now underway to harness the insights gleaned from this study into further investigations to benefit patients. The study team has started planning the VANCE trial biomarker studies, which aim to identify biomarkers in the patient’s immune system and in EBV CTL therapy. A comprehensive analysis of the Phase II EBV CTL trial conducted at NCCS that identifies biomarkers will be presented at the European Society of Medical Oncology (ESMO) Asia Congress in Singapore from 6 to 8 December 2024. These results are crucial for validation that will precede the VANCE trial biomarker studies.

###

Study citation:  Toh, H. C., Yang, M.-H., Wang, H.-M., Hsieh, C. Y., Chitapanarux, I., Ho, K. F., Hong, R.-L., Ang, M. K., Colevas, A. D., Sirachainan, E., Lertbutsayanukul, C., Ho, G. F., Nadler, E., Algazi, A., Lulla, P., Wirth, L. J., Wirasorn, K., Liu, Y. C., Ang, S. F., … Samol, J. (2024). Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: Vance, an international randomized phase III trial. Annals of Oncology. DOI: 10.1016/j.annonc.2024.08.2344

-END-

For media enquiries, please contact:

Dharshini Subbiah

National Cancer Centre Singapore

Corporate Communications

Email   : dharshini.subbiah@nccs.com.sg

Mobile : 9616 7532

About the National Cancer Centre Singapore

The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer. In addition to offering holistic and multidisciplinary oncology care, our clinicians and scientists collaborate with local and international partners to conduct robust, cutting-edge clinical and translational research. To achieve its vision of being a global leading cancer centre, NCCS offers world-class care and shares its depth of experience and expertise by training local and overseas medical professionals.

To meet growing healthcare needs, the new NCCS building opened in 2023 with increased capacity and expanded facilities dedicated to cancer care, rehabilitation, research and education. To give patients the best treatment outcomes, advanced and innovative treatment such as proton therapy is offered at the new Goh Cheng Liang Proton Therapy Centre at NCCS.

In 2024, NCCS celebrates its silver anniversary, celebrating 25 years of advancing cancer care from breakthroughs to healing.

END



ELSE PRESS RELEASES FROM THIS DATE:

Call for applications: Participation in the 12th Heidelberg Laureate Forum for Outstanding Young Researchers in Mathematics and Computer Science

Call for applications: Participation in the 12th Heidelberg Laureate Forum for Outstanding Young Researchers in Mathematics and Computer Science
2024-11-11
The application process for the 12th Heidelberg Laureate Forum has begun! Young researchers in mathematics and computer science from all over the world can apply for one of the 200 exclusive spots to participate in the Heidelberg Laureate Forum (HLF), an annual networking conference. The HLF offers all accepted young researchers the unique opportunity to interact with the laureates of the most prestigious prizes in the fields of mathematics and computer science. Traditionally, the recipients of the Abel Prize, the ACM A.M. Turing Award, the ACM Prize in Computing, ...

A milestone for reproductive medicine: Producing viable eggs from undeveloped oocytes through In vitro technology

A milestone for reproductive medicine: Producing viable eggs from undeveloped oocytes through In vitro technology
2024-11-11
Mature egg cells, or oocytes, are essential for fertilization in assisted reproductive technologies. However, some ‘denuded’ oocytes, or those lacking the protective granulosa cell layer, fail to mature. Now, in a new study by researchers at Shinshu University, the team has developed a method to culture mature oocytes from these denuded oocytes in the lab. This innovative approach holds promise for overcoming significant challenges in reproductive science, marking a major advancement in fertility research. Assisted ...

Vast majority of Trump voters believe American values and prosperity are ‘under threat’

2024-11-11
Almost nine out of ten voters who supported Donald Trump for US President believe that America’s values, traditions and future economic prosperity are under threat – double the number of Kamala Harris supporters.  This is according to new data from Cambridge University’s Political Psychology lab, who worked with YouGov to conduct an opinion poll of US voters shortly before the election.* Some 89% of Trump voters agree that “American values and beliefs are being undermined and cherished traditions are under threat” compared ...

Scientists investigate if red grape chemical can keep bowel cancer at bay

2024-11-11
Cancer Research UK-funded scientists are finding out if an ingredient commonly found in grape juice and wine could keep bowel cancer at bay. Resveratrol – a naturally occurring ingredient found in grapes, blueberries, raspberries and peanuts – will be tested as a potential cancer prevention drug as part of the Cancer Research UK-funded COLO-PREVENT trial. The trial is led from the University of Leicester and the National Institute for Health and Social Care Research (NIHR) Leicester Biomedical Research Centre. The trial ...

The refrigerator as a harbinger of a better life

2024-11-09
To get a good sense of a country’s level of development, you need to look at the items people have in their homes, according to economists Rutger Schilpzand and Jeroen Smits from Radboud University. Research on low- and middle-income countries often focuses on income, health or education, but that doesn’t tell you the full story of a country’s situation. ‘That’s why, for the first time, we are mapping out how the material wealth of households is developing,’ Schilpzand explains. The researchers coin this material wealth growth for households the 'domestic transition'. ...

Windfall profits from oil and gas could cover climate payments

2024-11-09
A central issue at the UN Climate Change Conference, set to start on November 11, will be the negotiations on new payments from industrialized nations to poorer countries. However, the question of whether and how these payments will be financed remains highly controversial. The study by an international team of researchers, with participation by the Technical University of Munich (TUM), has now revealed: The windfall profits alone taken in by oil and gas companies due to the 2022 energy crisis would have been sufficient to cover the existing commitments of the industrialized nations for nearly five years. The researchers ...

Heartier Heinz? How scientists are learning to help tomatoes beat the heat

2024-11-08
PROVIDENCE, R.I. [Brown University] — By studying tomato varieties that produce fruit in exceptionally hot growing seasons, biologists at Brown University identified the growth cycle phase when tomatoes are most vulnerable to extreme heat, as well as the molecular mechanisms that make the plants more heat tolerant. The discovery, detailed in a study in Current Biology, could inform a key strategy to protect the food supply in the face of climate instability, the researchers said. Agricultural productivity is particularly vulnerable to climate change, the study noted, and rising temperatures are predicted to reduce crop yields by 2.5% to 16% for every ...

Breaking carbon–hydrogen bonds to make complex molecules

Breaking carbon–hydrogen bonds to make complex molecules
2024-11-08
A team of scientists led by Caltech and Emory University has synthesized a highly complex natural molecule using a novel strategy that functionalizes normally nonreactive bonds, called carbon–hydrogen (C–H) bonds. The work demonstrates a new category of reactions that organic chemists can consider as they work to create natural products that could be used in pharmaceuticals or new materials, or to produce organic chemicals in more sustainable ways.   "This work moves the field forward by showing the power of C–H functionalization," says ...

Sometimes you're the windshield: Utah State University researcher says vehicles cause significant bee deaths

Sometimes youre the windshield: Utah State University researcher says vehicles cause significant bee deaths
2024-11-08
LOGAN, UTAH, USA -- When a large mammal such as a deer or a moose is struck by a motor vehicle, the damage is usually dramatic. To reduce these unfortunate events, transportation officials have teamed with wildlife researchers to place warning signs, and to construct wildlife underpasses and overpasses, to mitigate mishaps along animal migration paths. In contrast, collisions with much smaller bees often go unnoticed or are perceived by motorists as simply an annoying splat on a windshield. The significance, Utah State University ...

AMS Science Preview: Turbulence & thunderstorms, heat stress, future derechos

2024-11-08
The American Meteorological Society continuously publishes research on climate, weather, and water in its 12 journals. Many of these articles are available for early online access–they are peer-reviewed, but not yet in their final published form. Below is a selection of articles published early online recently. Some articles are open-access; to view others, members of the media can contact kpflaumer@ametsoc.org for press login credentials. JOURNAL ARTICLES A New Heat Stress Index For Climate Change Assessment Bulletin of the American Meteorological Society Heat Index may dramatically underestimate heat stress in extreme temperatures. This work compares the ...

LAST 30 PRESS RELEASES:

From traditional to technological: Advancements in fresco conservation

Design and imagination as essential tools during the climate crisis

Innovating archaeology: HKU scholars utilize immersive 3D tech to document and study the human past

What's the story, morning glory?

The unsolved mystery sounds of the Southern Ocean #ASA187

These wild chimpanzees play as adults to better cooperate as a group

Physical activity and all-cause mortality by age in 4 multinational megacohorts

Prenatal diet and infant growth from birth to age 24 months

Obesity prevention at an early age

New method for designing artificial proteins

MSU expert: How AI can help people understand research and increase trust in science

​​​​​​​Urgent need to enable more farmers and contractors to revive England’s network of hedgerows

ASH inclusion program retained and engaged hematologists underrepresented in field, 20-year analysis shows

How anti-obesity drugs are linked to food waste

Discovery explains kidney damage caused by blood pressure drugs

NYU Langone performs world’s first fully robotic double lung transplant

APSS accepting sleep and circadian research abstracts and session proposals for SLEEP 2025 in Seattle

DNA repair: A look inside the cell’s ‘repair café’

Astronomers take the first close-up picture of a star outside our galaxy

Here’s something Americans agree on: Sports build character

Engineering nature’s blueprint: Dendron-based assemblies for chlorophyll’s materials

Study reveals how cell types shape human brain networks

New genetic explanation for heart condition revealed

Poor mental health linked to browsing negative content online

People with migraine at high risk of depression during pandemic

Climate-driven hazards increases risk for millions of coastal residents, study finds

Females sleep less, awaken more frequently than males

Most Americans want primary care providers to address mental health

Millions of Americans hurt by others’ drinking, drug use: study

Plasma-derived atomic hydrogen advances low-temperature CO2 methanation at high yield

[Press-News.org] Largest T cell clinical trial in solid tumors heralds new era in precision immunotherapy
The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed